3 February 2021 - In Vitro
Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
et al., bioRxiv, doi:10.1101/2021.02.03.429164 (Preprint) (In Vitro)
In Silico, In Vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/imdevimab in hamsters.
Rothenberger et al., 2/3/2021, preprint, 65 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.